Kesmalea Therapeutics

A New Approach To Alzheimer's Treatment

About this Event

Few diseases are as devastating as Alzheimer’s. More than 7 million Americans are living with it, while millions of families watch someone they love gradually lose their memory, independence and connection to the people around them.

Kesmalea Therapeutics is developing an important new approach to treating Alzheimer’s: an oral, brain-penetrant drug designed to selectively eliminate pathological tau, a protein strongly associated with Alzheimer’s progression and neuronal loss. Rather than suppressing production of all tau, Kesmalea’s lead degraders are designed to selectively remove pathological forms while preserving healthy tau. Early results are compelling with greater than 90% tau degradation.

Join our fireside chat with:
  • Robert Johnson: CEO, Kesmalea, an accomplished biotechnology executive with more than 25 years of experience building and leading innovative life sciences companies. Previously, he served as CEO of Adrestia Therapeutics, which was acquired by Insmed in 2023 and co-founded Affinia Therapeutics, a gene therapy company that secured a $1.6 billion strategic alliance with Vertex Pharmaceuticals. He holds a degree in Molecular Cell Biology from the University of Nottingham in the United Kingdom
  • Stephen J. Haggarty, PhD: Professor of Neurology, Harvard Medical School and Director, Chemical Neurobiology Laboratory, Massachusetts General Hospital Dr. Haggarty has dedicated his career to advancing novel therapeutics for neurodegenerative and neuropsychiatric disorders. He also serves as Co-Director of the MGH Precision Therapeutics Unit and Scientific Director of Neurobiology at the MGH Center for the Neuroscience of Psychedelics.

Watch now to hear about the progress in treating Alzheimer’s and how their platform has the potential to treat additional indications including Parkinson’s, Huntington’s, and other neurological diseases.

Video On Demand

– Recorded

October 13

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.